European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - drugs used in diabetes - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease. 

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - idiopathic pulmonary fibrosis - antineoplastic agents - ofev is indicated in adults for the treatment of idiopathic pulmonary fibrosis (ipf).

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - carcinoma, non-small-cell lung - antineoplastic agents - vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after first line chemotherapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tasonermin - powder and solvent for solution for infusion - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tasonermin - powder for solution for infusion - 1mg

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformin - diabetes mellitus, type 2 - drugs used in diabetes, - treatment of adult patients with type-2 diabetes mellitus:jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

European Union - English - EMA (European Medicines Agency)

bayer ag - telmisartan - hypertension - agents acting on the renin-angiotensin system - hypertensiontreatment of essential hypertension in adults.cardiovascular preventionreduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertension - angiotensin ii antagonists, plain - hypertensiontreatment of essential hypertension in adults.cardiovascular preventionreduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.micardisplus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.micardisplus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on micardisplus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertension - cardiovascular system - treatment of essential hypertension in adults:add on therapyonduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.replacement therapyadult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of onduarp containing the same component doses.